Figure 4.

Combined treatment with an anti‐IL‐6 Ab and the WNT5A antagonist Box5 more effectively impairs the migration and invasion of BRAFi‐R melanoma cells. (A, B) HTB63‐R and (C, D) A375‐R cells were exposed to an IL‐6 Ab and/or Box5. Their migratory and invasive responses were evaluated as described in the methods. Cells were pretreated with vehicle, IL‐6 Ab or/and Box5 for 48 h, after which migration/invasion assays were initiated and performed for 24 h in the presence of freshly added vehicle, IL‐6 Ab or/and Box5. After the assays were completed, the numbers of migrating or invading cells were quantified by counting the cells with NIH imagej ^® software and are shown as the relative cell migration or invasion. The results (n = 4) are given in relation to that of vehicle‐treated control cells (n = 4) and given as the mean ± SEM. Statistical analyses were performed using ANOVA and the Newman–Keuls multiple comparison test; *P < 0.05, **P < 0.01, ***P < 0.001.